Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| IBM | Powell Industries, Inc. | Tempus AI | |
|---|---|---|---|
| Moat rating | narrow IBM's FY2025 10-K describes "a highly competitive environment" with "hundreds of competitors" and says IBM is "regularly exposed to new competitors" as it executes its hybrid-cloud/AI strategy, while differentiating through "incumbency with enterprises" and "client relationships and trust" — a real but narrow moat, not a wide one. | none The FY2025 10-K (filed 2025-11-19) says the company believes its integration capabilities, technical and project management acumen, application engineering expertise and specialty contracting experience 'give us a sustainable competitive advantage in our markets', and that 'a significant portion of our business is from repeat customers', many times involving EPC firms 'with whom we often have long, established relationships'. Neither the filing nor Powell's record shows that edge protecting returns. Item 1A warns 'Our industry is highly competitive' and says certain competitors 'may have lower cost structures' and 'may, therefore, be able to provide their products or services at lower prices'. Item 1 says products are 'typically awarded in competitive bid situations' and that projects 'are typically non-recurring.' Stored fundamentals from Powell's filings show operating margin between -4.9% and 7.1% in every fiscal year from FY2011 to FY2022, with operating losses in FY2017 (-$19.3M on $395.9M of revenue) and FY2018 (-$9.1M on $448.7M). Operating margin has since risen to 19.7% in FY2025 ($217.9M on $1,104.3M), but the 10-K credits the gross-margin gain to 'favorable volume leverage and strong project execution in a stable pricing environment', not to a competitive edge. A self-described advantage that left operating margin no higher than 7.1% in any year from FY2011 to FY2022 is not shown to be a moat, so the band is none. | narrow The FY2025 10-K documents a real asset: a network "connected in some way to more than 55% of all oncologists practicing in the United States" and "more than 65% of all academic medical centers," via "more than 700 unique data connections" across "more than 5,000 healthcare institution sites," with "broad data rights, including the rights to longitudinally updated data." Not eroding: revenue $693.4M to $1,271.8M (+83%), net loss narrowed from $705.8M to $245.0M. Not wide: still loss-making against "an accumulated deficit of $2.4 billion," with payment received on only "approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests." |
| Moat type | switching costs The 10-K roots IBM's differentiation in "incumbency with enterprises" and "client relationships and trust" — installed-base lock-in across its hybrid-cloud platform (Red Hat) and enterprise software and infrastructure raises switching costs. | none The 10-K describes engineering know-how, not protected technology or lock-in. It says 'We consider our engineering, project management, systems integration and technical support capabilities vital to the success of our business', that 'Powell's expertise in vacuum circuit breaker engineering is internationally recognized', and that unpatented technology, including engineering technical skills and know-how, 'is important to our overall business'. It also says 'we believe that the growth of our business will depend primarily upon the quality of our products and our relationships with our customers, rather than the extent of our patent protection', so patents are not the source. Switching costs are not shown: projects are 'typically awarded in competitive bid situations' and 'typically non-recurring', even though 'a significant portion of our business is from repeat customers'. The same filing says some competitors 'are significantly larger and have substantially greater global resources such as engineering, manufacturing and marketing', so the know-how is a capability rivals also bring to each bid, not a demonstrated moat source; the type is none. | network effects The filing states the mechanism: "Each product line is designed to enable and enhance the other, thereby creating network effects." That is the filing's own characterisation, so the rating rests on corroborating facts: 700+ data connections across 5,000+ sites with longitudinal rights; roughly 801,000 tests in FY2025 (about 340,500 Oncology) feeding the records Insights licenses; Insights working with "19 of the 20 largest public pharmaceutical companies based on 2024 revenue" at "approximately 126%" net revenue retention. Intangibles fit less well: the xT PMA, ADLT status, Paige's clearance and five CAP/CLIA labs are real, but named peers hold comparable approvals. |
| Leadership | fast follower An enterprise incumbent that differentiates via "incumbency with enterprises" but is "regularly exposed to new competitors" in its hybrid-cloud/AI push (FY2025 10-K) — a follower in the current AI cycle rather than its leader. | at parity The 10-K gives no share or rank. It says Powell competes 'with a small number of multinational competitors', naming ABB, Eaton, Schneider and Siemens Industries, and that some are 'significantly larger and have substantially greater global resources'. It adds that bid evaluation varies 'from project to project', covering technical support, engineering and manufacturing capability, equipment rating, delivered value, scheduling and price. Powell therefore competes bid by bid alongside those multinationals rather than leading the category. | at parity The filing claims no ranked lead; its positional language is hedged, as in "one of the largest sequencers of cancer patients... in the United States." Two disclosures cut the other way: the reimbursement goal is to become "more in line with other NGS providers who have adopted similar strategies, such as FMI and Guardant," and competitors "may have longer operating histories; larger customer bases; greater brand recognition and market penetration." Competition names Foundation Medicine (Roche), Caris, Guardant, Natera, Neogenomics, Quest, LabCorp, Flatiron, IQVIA, ConcertAI and major CROs, all unranked. Scaled positions on both sides support parity, not a top position. |
| Pricing power | moderate Gross margin is high and rising (54.9% FY2021 to 58.2% FY2025) on a software-mix shift, but "price" is a principal method of competition per the 10-K and consulting/infrastructure remain price-competitive. | weak The 10-K says gross margin rose to 29% of revenue in FY2025 from 27% in FY2024, 'due to favorable volume leverage and strong project execution in a stable pricing environment'. The 10-Q for the quarter ended June 30, 2026 (https://www.sec.gov/Archives/edgar/data/80420/000008042026000107/powl-20260630.htm) gives the same reason for 30% in the first nine months of FY2026, so neither filing credits price. Before this upcycle, stored fundamentals from Powell's filings show gross margin between 12.8% and 21.6% in every fiscal year from FY2011 to FY2022 (FY2022: $85.0M of gross profit on $532.6M of revenue, about 16%), which fits cyclical volume leverage more than pricing power. The limits are explicit: the 10-K says 'Fixed-price contracts can limit our ability to pass these increases to our customers', and Item 1A says certain competitors 'may, therefore, be able to provide their products or services at lower prices'. The one offset is cost pass-through, not price-setting: the 10-K says 'we believe we can manage this volatility through contract pricing adjustments'. Pricing power is rated weak. | weak Diagnostics prices are administered: after a CPT code is set, "CMS, establish payment levels and coverage rules under Medicare," delegating to MACs, while "Private payers establish their rates and coverage rules independently." Average revenue per Oncology test rose from about $1,510 to about $1,600, "driven primarily by increased Medicare reimbursement rates" — the payer moved the price. Collection came on "approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests," and payer "cost-saving initiatives... are likely to result in pricing pressures." The moderate pocket is confined to Data and applications ($316.4M of $1,271.8M). |
| Summary | IBM's moat rests on deep enterprise incumbency — sticky installed-base relationships across hybrid cloud (Red Hat), enterprise software, and mission-critical infrastructure, plus brand and a large patent base. But its own FY2025 10-K frames "a highly competitive environment" with "hundreds of competitors" and says IBM is "regularly exposed to new competitors" as it pursues hybrid cloud and AI, so the moat is durable but narrow and contested in the AI/cloud growth arena. | Powell designs, builds and services custom-engineered power-distribution packages: power control rooms, E-Houses, switchgear and medium-voltage breakers. Its FY2025 10-K says the company believes its integration, project-management and application-engineering capabilities 'give us a sustainable competitive advantage in our markets', and that a significant portion of its business comes from repeat customers, often through EPC firms with which it has long relationships. The record does not show that edge protecting returns. Work is typically won in competitive bids, projects are typically non-recurring, and the 10-K names ABB, Eaton, Schneider and Siemens Industries as principal competitors, some of which it calls significantly larger. The company says it believes growth depends on product quality and customer relationships rather than patents. Stored fundamentals from Powell's filings show operating margin between -4.9% and 7.1% in every fiscal year from FY2011 to FY2022, with operating losses in FY2017 and FY2018. In the current cycle, gross margin reached 29% in FY2025 (10-K) and 30% in the first nine months of FY2026 (10-Q, quarter ended June 30, 2026, https://www.sec.gov/Archives/edgar/data/80420/000008042026000107/powl-20260630.htm). Both filings attribute that to favorable volume leverage and strong project execution 'in a stable pricing environment', not to price increases. The same 10-Q reports backlog of $2.4 billion and says diversification into electric utility and data centers 'has reduced the cyclicality of our business.' It also cautions that as data center projects become a larger component of backlog and revenues, the product mix may shift, 'as such projects will likely require less custom engineered-to-order equipment and systems than other end markets', which is the custom-engineering skill the claimed edge rests on. | Tempus AI's durable asset is an installed provider network and the longitudinal data rights attached to it, not any single assay: connections to more than 55% of practicing U.S. oncologists and more than 65% of academic medical centers, 700+ data connections across 5,000+ institution sites. That network makes the linked clinical-molecular database sellable — Insights serves 19 of the 20 largest public pharmaceutical companies by 2024 revenue at roughly 126% net revenue retention, and the trial network (1,400+ trials signed, 40,000+ patients identified) depends on the sequencing base. Economics are improving: revenue up 83% to $1.27B, net loss down from $705.8M to $245.0M. It stops short of wide on the filing's own terms — a $2.4B accumulated deficit, payment on only ~55% of oncology and ~50% of hereditary tests, and Diagnostics prices set by CMS, MACs and private payers. |
| Chain position | A hybrid-cloud platform, enterprise-AI (watsonx), and consulting provider to large enterprises — a software/cloud layer of the AI stack. | Supplies custom-engineered switchgear and power control rooms to oil and gas, utility and commercial/industrial projects. Its Q3 FY2026 bookings included 'a data center project valued at over $400 million' (10-Q, quarter ended June 30, 2026, https://www.sec.gov/Archives/edgar/data/80420/000008042026000107/powl-20260630.htm). | Tempus sits between clinical care and pharma R&D. It ingests data from 5,000+ institution sites, runs five CAP/CLIA labs (Chicago, Atlanta, Raleigh, Aliso Viejo, Minneapolis via OneOme), and sells Diagnostics to providers and payers ($955.4M FY2025, +111%, administered) and Data and applications to pharma ($316.4M, +31%, negotiated). The clinical output is the data business's input. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.06 at weight 0.20 · swarm bearish Editorial prior, not backtested. | -0.06 at weight 0.20 · swarm bearish Editorial prior, not backtested. | -0.01 at weight 0.20 · swarm neutral Editorial prior, not backtested. |